DMXAA (Vadimezan)

DMXAA (Vadimezan)は、DT-ジアホラーゼ(NAD(P)H:キノン酸化還元酵素EC 1.6.99.2)の競争的阻害剤で、Ki が20 μM 、IC50が62.5 μMです。

目録号S1537
4.5 5 1レビュー
価格 在庫  
USD 151 In stock
USD 176 In stock
USD 466 In stock
USD 1222 In stock

DMXAA (Vadimezan) 化学構造
分子量: 282.29

品質と確認

カスタマーレビュー(1)

Quality Control & MSDS

製品情報

  • Compare VDA Inhibitors
    VDA阻害剤を比較
  • 研究分野

製品の説明

生物活性

情報 DMXAA (Vadimezan)は、DT-ジアホラーゼ(NAD(P)H:キノン酸化還元酵素EC 1.6.99.2)の競争的阻害剤で、Ki が20 μM 、IC50が62.5 μMです。
目標 DT-diaphorase DT-diaphorase
IC50 62.5 μM 20 μM (Ki) [1]
In vitro試験 In DLD-1 human colon carcinoma cells, DMXAA inhibits DT-diaphorase activity without significant effects on the activity of cytochrome b5 reductase and cytochrome P450 reductase. Combination of menadione and DMXAA leads to an increase in the antiproliferative activity of DLD-1 cells. [1] DMXAA, as an antiviral agent, inhibits VSV-induced cytotoxicity and influenza virus replication in RAW 264.7 macrophages. [2] A recent study shows that DMXAA has non-immune-mediated inhibitory effects against several kinase members of VEGFR (vascular endothelial growth factor receptor), such as VEGFR2 signalling in human umbilical vein endothelial cells. [3]
In vivo試験 DMXAA treatment significantly protects C57BL/6J mice infected i.n. with 200 p.f.u. mouse-adapted H1N1 influenza PR8 virus with 60% survival, while the control group only exhibited 20% survival. [2] DMXAA significantly delays tumor growth induced by chemical carcinogen, increases the time to tumor doubling and increases time from treatment to euthanasia. After the treatment of DMXAA, median tumor doubling time, median tumour tripling time and median time from treatment to euthanasia in tumor-bearing animals are increased by approximately 4.4-, 1.8- and 2.7-fold, respectively. [4]
臨床試験 DMXAA is currently in Phase II clinical trials in patients with non-small cell lung cancer.
特集

推薦された実験操作 (公開の文献だけ)

キナーゼアッセイ: [1]

DT-diaphorase activity and kinetic analysis of enzyme inhibition Purified DT-diaphorase enzyme activity is assayed by measuring the reduction of cytochrome c at 550 nm on a Beckman DU 650 spectrophotometer. Each assay contains cytochrome c (70 μM), NADH (variable concentrations), purified DT-diaphorase (0.032 μg), and menadione (variable concentrations) in a final volume of 1 mL Tris–HCl buffer (50 mM, pH 7.4) containing 0.14% BSA. The reaction is started by the addition of NADH. Rates of reduction are calculated over the initial part of the reaction curve (30 seconds), and results are expressed in terms of μmol cytochrome c reduced/min/mg protein using a molar extinction coefficient of 21.1 mM−1 cm−1 for reduced cytochrome c. Enzyme assays are carried out at room temperature and all reactions are performed in triplicate. Inhibition of purified DT-diaphorase activity is performed by the inclusion of DMXAA (at various concentrations) in the reaction, and inhibition characteristics are determined by varying the concentration of NADH (constant menadione) or menadione (constant NADH) at several concentrations of inhibitor. Ki values are obtained by plotting 1/V against. The activity of DT-diaphorase in DLD-1 cells is determined by measuring the dicumarol-sensitive reduction of DCPIP at 600 nm. Briefly, DLD-1 cells in mid-exponential growth are harvested by scraping into ice-cold buffer (Tris–HCl, 25 mM, pH 7.4 and 250 mM sucrose) and sonicated on ice. Enzyme assay conditions are 2 mM NADH, 40 μM DCPIP, 20 μL of dicumarol (when required) in a final volume of 1 mL Tris–HCl (25 mM, pH 7.4) containing BSA (0.7 mg/mL). Results are expressed as the dicumarol-sensitive reduction of DCPIP using a molar extinction coefficient of 21 mM−1 cm−1. Protein levels are determined using the Bradford assay

細胞アッセイ: [1]

細胞系 DLD-1 and H460 cells
濃度 0-2 mM
処理時間 96 hours
方法 DLD-1 human colon carcinoma and H460 human non-small cell lung carcinoma cells are routinely maintained as monolayer cultures in RPMI 1640 culture medium supplemented with foetal calf serum (10%), sodium pyruvate (2 mM), penicillin/streptomycin (50 IU mL−1/50 μg mL-1) and l-glutamine (2 mM). Chemosensitivity is assessed using the MTT assay and all assays are performed under aerobic conditions. Briefly, cells are plated into each well of a 96-well culture plate and incubated overnight in an atmosphere containing 5% CO2. Culture medium is completely removed from each well and replaced with medium containing a range of drug concentrations. In the case of menadione alone, the duration of drug exposure is 1 hour, after which the cells are washed twice with Hanks' balanced salt solution prior to the addition of 200 μL fresh RPMI 1640 medium to each well of the plate. In the case of DMXAA alone, the duration of drug exposure is 3 hours. Following a four-day incubation, cell survival is determined using the MTT assay. For combinations of DMXAA with menadione, cells are initially set up and a non-toxic (>95% cell survival) concentration of DMXAA is selected. Cells are then initially exposed to DMXAA (2 mM) for a period of 2 hours, following which the medium is removed and replaced with medium containing the inhibitor (DMXAA at a constant concentration of 2 mM) and menadione (at a range of drug concentrations). Following a further 7-hour incubation, cells are washed twice with Hanks' balanced salt solution prior to the addition of growth medium.

動物実験: [4]

動物モデル Chemical carcinogen (NMU) is injected into female Wistar rats.
製剤 DMXAA is dissolved in 5% sodium bicarbonate.
投薬量 ≤300 mg/kg
管理 Administered via i.p.
1

参考

化学情報

Download DMXAA (Vadimezan) SDF
分子量 282.29
化学式

C17H14O4

CAS No. 117570-53-3
別名 AS-1404, 5,6-MeXAA, NSC-640488, Vadimezan
溶解度 (25°C)
  • DMSO 7 mg/mL
  • 水 <1 mg/mL
  • エタノール <1 mg/mL
保管 2年 -20°C
6月-80°Cin DMSO
化学名 2-(5,6-dimethyl-9-oxo-9H-xanthen-4-yl)acetic acid

研究分野

カスタマーレビュー (1)


Click to enlarge
Rating
Source , , Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.01.184. DMXAA (Vadimezan) purchased from Selleck
Method Western blot
Cell Lines HCT116 p53 null cells
Concentrations 5 uM
Incubation Time 24 h
Results M344 causes ER stress and increase the expression of ATF4, ATF3, CHOP.

技術サポート&よくある質問(FAQ)

顧客がするかもしれない質問に対する答えは、指示を取り扱っている阻害剤で見つかります。話題は、貯蔵液(阻害剤と特別な注意を細胞ベースの分析法と動物のために必要とする問題を保存することは実験します)を準備する方法を含みます。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の問い合わせをするならば、メッセージを残してください。

* 必須

Related 脈管途絶しているエージェント 阻害剤

  • Plinabulin (NPI-2358)

    Plinabulin (NPI-2358)はチュービュリンを解重合しているエージェントで、9.8~18nMのIC50で、腫瘍細胞を妨げます。

  • Saracatinib (AZD0530)

    Saracatinib(AZD0530)は、c-SrcのためのSrc阻害剤で、IC50 が2.7 nMです。

  • FG-4592

    FG-4592は、低酸素誘発要因アルファ-サブユニット・プロリルヒドロキシラーゼ阻害剤です。

  • Dovitinib (TKI-258, CHIR-258)

    Dovitinib (TKI-258, CHIR-258)は非常に強い、新型の多い標的阻害剤、FLT3、c - kit、受容体、マウス/2/3、成長因子受容体と球コロニー刺激因子受容体ßに作用する時、IC50がそれぞれ 1 nM, 2 nM, 5 nM, 10 nM, 8 nM, 27 nM と 36 nMになる。

  • Tandutinib (MLN518)

    Tandutinib (MLN518)は、FLT3、PDGFRとc-キットのATP競争的で非常に選択的な阻害剤で、 IC50がそれぞれ 0.22 μM、0.20 μM 、0.17 μMです。

  • ENMD-2076

    ENMD-2076は、有糸分裂キナーゼ・オーロラAとオーロラBの選択的な阻害剤で、IC50 がそれぞれ 14 nM と 350 nMです。

  • 2-Methoxyestradiol (2-MeOE2)

    2-Methoxyestradiol (2-MeOE2)は、内在性エストロゲン代謝物質と天然に存在する哺乳類のチュービュリン重合阻害剤です。

  • PD173074

    PD173074は、有力なFGFR1</b> 阻害剤でIC50 が ~25 nM。

  • Bafetinib (INNO-406)

    Bafetinib(INNO-406)は、5.8nMと19nMのIC50による強力で選択的な二重Bcr-Abl/リン・チロシン・キナーゼ阻害剤です

  • Quizartinib (AC220)

    Quizartinib (AC220)は、FLT3の強力で選択的な阻害剤で、 FLT3-ITDとFLT3-WT自己リン酸化に作用すると、 IC50がそれぞれ 1.1 nM 、4.2 nMになる。

最近見られたアイテム

Tags: DMXAA (Vadimezan)を買う | DMXAA (Vadimezan)供給者 | DMXAA (Vadimezan)を購入する | DMXAA (Vadimezan)費用 | DMXAA (Vadimezan)生産者 | オーダーDMXAA (Vadimezan) | DMXAA (Vadimezan)代理店
お問い合わせ